General Information of the Drug (ID: M6APDG04300)
Name
VM-501
Synonyms
IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D05XKW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interleukin-11 (IL11)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
Response Summary Interleukin-11 (IL11) is a therapeutic target for VM-501. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of VM-501 through regulating the expression of Interleukin-11 (IL11). [1], [2]
References
Ref 1 YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer. 2019 Nov 18;18(1):163. doi: 10.1186/s12943-019-1082-3.
Ref 2 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.